Results from a Phase III trial show that the administration of Tykerb in combination with Herceptin increases progression free survival in HER2 positive breast cancer
Filed under: kinase | Tagged: EGFR, ErbB-2, ErbB2, Genentech, GlaxoSmithKline, GSK, GSK-572016, GSK572016, HER2, Herceptin, kinase, Lapatinib, Roche, Tykerb, tyverb |
Δ
Leave a comment